The resurrection of spironolactone on its golden anniversary

American Journal of Critical Care

Volumn 13, Issue 2, 2004, Pages 162-165

  Futterman, Laurie G ^a   Lemberg, Louis ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CARVEDILOL; DIGOXIN; ENALAPRIL; EPLERENONE; EZETIMIBE; FUROSEMIDE; SODIUM CHLORIDE; SPIRONOLACTONE; ALDOSTERONE ANTAGONIST; DRUG DERIVATIVE;

ACUTE HEART INFARCTION; AGED; ARTICLE; CASE REPORT; CONGESTIVE HEART FAILURE; ELECTROCARDIOGRAM; FEMALE; HEART VENTRICLE EXTRASYSTOLE; HUMAN; PHYSICAL EXAMINATION; SODIUM RESTRICTION; DRUG EFFECT; ELECTROLYTE BALANCE;

AGED; ALDOSTERONE ANTAGONISTS; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; SPIRONOLACTONE; WATER-ELECTROLYTE BALANCE;

EID: 3042699595     PISSN: 10623264     EISSN: None     Source Type: Journal    
DOI: 10.4037/ajcc2004.13.2.162     Document Type: Article

References (12)

1. Selwyn A. Eplerenone blocks aldosterone, reduces post-MI mortality. Intern Med World Rep. Sept 2003;18:8.
2. Campese V, Rezvani F. Aldosterone blockade for the treatment of hypertension. University Reports on Recent Advances in Aldosterone Blockade: The Emerging Treatment for Cardiorenal Diseases. Newtown, Pa: Associates in Medical Marketing; 2003;2:1-9.
3. Flack JM, Oparil S, Pratt JH, et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black patients and white patients. J Am Coll Cardiol. 2003;41:1148-1155.
4. Pitt B, Reichek N, Metscher B, et al. Efficacy and safety of eplerenone, enalapril, and eplerenone/enalapril in combination therapy in patients with left ventricular hypertrophy. Am J Hypertens. 2002;15(suppl 1).
5. Epstein M, Buckalew V, Altamirano J, et al. Eplerenone reduces proteinuria in type II diabetes mellitus: implications for aldosterone involvement in the pathogenesis of renal dysfunction. J Am Coll Cardiol. 2002;39(suppl A):A843.
6. Mantero F, Lucarelli G. Aldosterone antagonists in hypertension and heart failure. Ann Endocrinol. 2000;61:52-60.
7. Delyani JA, Rocha R, Cook CS, et al. Eplerenone: a selective aldosterone receptor antagonist (SARA). Cardiovasc Drug Rev. 2001;19:185-200.
8. Friedberg CK. Treatment of congestive heart failure. In: Diseases of the Heart. 3rd ed. Philadelphia, Pa: WB Saunders; 1966:408-410.
9. Lamb RE, Folstad J. Aldosterone receptor antagonists: focus on eplerenone. Prog Cardiovasc Nurs. Winter 2003;18:54-59.
10. DRUGDEX drug evaluations: eplerenone. In: Klasko RK, ed. DRUGDEX System. Greenwood Village, Colo: Thomson MICROMEDEX (edition expires September 2003).
11. Stier CT Jr, Chander PN, Rocha R. Aldosterone as a mediator in cardiovascular injury. Cardiol Rev. 2002;10:97-107.
12. Weber MA. Clinical implications of aldosterone blockade. Am Heart J. 2002;144(suppl 5):S12-S18.